CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
CG Oncology (NASDAQ: CGON) has scheduled a conference call and webcast for December 5, 2024, at 7 am CST to discuss results from their Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The call will feature Dr. Mark Tyson, II, urologic oncologist at Mayo Clinic and lead investigator of the BOND-003 study, who will present the results as a late-breaking abstract at the Society of Urologic Oncology (SUO) 25th Annual Meeting in Dallas at 11:45 am CST. The webcast will be accessible through the company's Investor Relations website, with an archive available after the call.
CG Oncology (NASDAQ: CGON) ha programmato una conferenza telefonica e un webcast per il 5 dicembre 2024, alle 7:00 CST, per discutere i risultati del loro studio di fase 3 BOND-003 sulla monoterapia con cretostimogene in pazienti con carcinoma della vescica non muscolo-invasivo (NMIBC) ad alto rischio e non responsivi al BCG.
Durante la chiamata interverrà Dr. Mark Tyson, II, oncologo urologico presso la Mayo Clinic e principale investigatore dello studio BOND-003, che presenterà i risultati come un abstract tardivo al 25° Congresso Annuale della Society of Urologic Oncology (SUO) a Dallas, alle 11:45 CST. Il webcast sarà accessibile tramite il sito web delle Relazioni con gli Investitori dell'azienda, con un archivio disponibile dopo la chiamata.
CG Oncology (NASDAQ: CGON) ha programado una llamada y un webcast para el 5 de diciembre de 2024, a las 7 a.m. CST para discutir los resultados de su ensayo de fase 3 BOND-003 sobre la monoterapia con cretostimogene en cáncer de vejiga no músculo invasivo (NMIBC) de alto riesgo que no responde a BCG.
La llamada contará con la participación del Dr. Mark Tyson, II, oncólogo urológico en la Clínica Mayo y líder investigador del estudio BOND-003, quien presentará los resultados como un resumen de última hora en el 25º Congreso Anual de la Sociedad de Oncología Urológica (SUO) en Dallas a las 11:45 a.m. CST. El webcast será accesible a través del sitio web de Relaciones con Inversionistas de la empresa, con un archivo disponible después de la llamada.
CG Oncology (NASDAQ: CGON)는 2024년 12월 5일 오전 7시 CST에 고위험 BCG에 반응하지 않는 비근육 침습성 방광암(NMIBC)에 대한 크레토스티모젠 단독 요법의 3상 BOND-003 시험 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다.
전화 회의에는 Dr. Mark Tyson, II가 참석할 예정이며, 그는 메이요 클리닉의 비뇨기계 종양학자로서 BOND-003 연구의 수석 연구원으로 있습니다. 그는 CST 오전 11시 45분에 달라스에서 열리는 비뇨기 종양학회(SUO) 제25회 연례 회의에서 결과를 늦게 발표하는 초록으로 소개할 것입니다. 웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 호출 후에는 아카이브도 제공됩니다.
CG Oncology (NASDAQ: CGON) a programmé une conférence téléphonique et un webinaire pour le 5 décembre 2024, à 7 heures CST, pour discuter des résultats de leur essai de phase 3 BOND-003 sur la monothérapie par créto-simogène dans le cancer de la vessie non musculo-invasif (NMIBC) à haut risque et non réceptif au BCG.
La conférence sera animée par Dr. Mark Tyson, II, oncologue urologique à la Mayo Clinic et chercheur principal de l'étude BOND-003, qui présentera les résultats sous forme d'abstract tardif lors du 25ème Congrès Annuel de la Société d'Urologie Oncologique (SUO) à Dallas à 11h45 CST. Le webinaire sera accessible via le site des Relations Investisseurs de l'entreprise, avec un archive disponible après l'appel.
CG Oncology (NASDAQ: CGON) hat eine Telefonkonferenz und ein Webcast für den 5. Dezember 2024, um 7 Uhr CST, angesetzt, um die Ergebnisse ihrer Phase-3-BOND-003-Studie zur Monotherapie mit Cretostimogen bei hochriskantem BCG-unempfindlichem nicht-muskelinvasivem Blasenkarzinom (NMIBC) zu besprechen.
In dem Gespräch wird Dr. Mark Tyson, II, urologischer Onkologe der Mayo Clinic und leitender Untersucher der BOND-003-Studie, die Ergebnisse als Late-Breaking-Abstract auf dem 25. Jahreskongress der Society of Urologic Oncology (SUO) in Dallas um 11:45 Uhr CST vorstellen. Das Webcast wird über die Investor-Relations-Website des Unternehmens zugänglich sein, mit einem Archiv, das nach dem Anruf verfügbar ist.
- None.
- None.
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition to company executives, this call will feature Mark Tyson, II, M.D., M.P.H., urologic oncologist at Mayo Clinic, and lead investigator in the BOND-003 study. Dr. Tyson is presenting the results as a late breaking abstract at the Society of Urologic Oncology (SUO) 25th Annual Meeting in Dallas, TX at 11:45 am CST on December 5, 2024.
Individuals can access the webcast via the link on the company's Investor Relations website, https://ir.cgoncology.com. An archive will be available following the completion of the call.
About Bladder Cancer
More than 83,000 people are estimated to be diagnosed with bladder cancer in 2024. NMIBC is the most common form of bladder cancer, representing approximately
About Cretostimogene Grenadenorepvec
Cretostimogene grenadenorepvec is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 250 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials; BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC. CG Oncology also has a Phase 2 trial, CORE-008, evaluating the safety and efficacy of cretostimogene in high-risk NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Forward Looking Statements
CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, the potential therapeutic benefits of cretostimogene for high-risk and intermediate-risk NMIBC patients. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: additional patient data related to cretostimogene that continues to become available may be inconsistent with the data produced as of the data cutoff, and further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; potential delays in the commencement, enrollment and completion of clinical trials; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Chau Cheng
Vice President, Investor Relations, CG Oncology
(949) 342-8939
chau.cheng@cgoncology.com
FAQ
When is CG Oncology (CGON) hosting its conference call for BOND-003 trial results?
What will be discussed in CG Oncology's (CGON) December 5 conference call?
Who is presenting the BOND-003 trial results at the SUO Annual Meeting?
How can investors access CG Oncology's (CGON) December 5 webcast?
